Bite Force, Botulinum Toxins, Type A
Conditions
Brief summary
This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units).
Detailed description
This study aimed to evaluate the duration of a reduced maximal voluntary bite force (MVBF) after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units). A control group did not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the incisors and first molars. The intervention group was comprised of individuals seeking aesthetic treatment for masseter reduction (n = 20), and the control group (n = 12) comprised of volunteers.
Interventions
DRUGBotulinum toxin type A
Single intervention
Sponsors
Umeå University
Mahidol University
Region Västerbotten
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 120 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy subjects seeking aesthetical treatment to reduce masseter muscle volume.
Exclusion criteria
Conditions or drugs affecting the central nervous system.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of bite force | Baseline, 4 weeks, 3 months, 6 months, 12 months. | Maximum voluntary bite force measured in Newtons at baseline, and change of bite force compared to baseline. |
Countries
Sweden
Outcome results
None listed